文献速递前列腺癌

磁共振成像为预估高危前列腺癌风险≤10%的患者提供前列腺癌预防试验风险计算器之外的附加价值

Magnetic Resonance Imaging Provides Added Value to the Prostate Cancer Prevention Trial Risk Calculator for Patients With Estimated Risk of High-grade Prostate Cancer Less Than or Equal to 10.
PubMed 文献 · Urology · 2016-12-02

本研究纳入2012年1月至2015年12月在本机构活检前接受前列腺磁共振成像的339例患者,比较前列腺癌预防试验风险计算器单独与联合磁共振成像模型的活检结局区分度。全部患者中两模型表现相似(AUC=0.74 vs 0.78,P=.06);预估高危(Gleason≥7)前列腺癌风险≤10%的患者中,联合磁共振成像模型优于单独模型(AUC=0.69 vs 0.60,P=.01)。

要点

  • 全部339例患者中,联合磁共振成像模型与单独风险计算器模型的AUC分别为0.74和0.78(P=.06)。
  • 预估高危前列腺癌风险≤10%的患者中,联合磁共振成像模型AUC=0.69优于单独模型AUC=0.60(P=.01)。
  • 该队列中,既往活检阴性者两模型区分度无显著差异(AUC=0.61 vs 0.63,P=.76);首次活检者联合磁共振成像模型显著改善(AUC=0.72 vs 0.60,P=.01)。

核心结论

  • 对于预估高危(Gleason≥7)前列腺癌风险≤10%的患者,前列腺磁共振成像联合前列腺癌预防试验风险计算器可显著改善临床风险区分度。
  • 作者认为这些患者应强烈考虑活检前行前列腺磁共振成像。

研究设计与样本

  • 回顾性分析2012年1月至2015年12月在本机构活检前接受前列腺磁共振成像的339例患者。
  • 磁共振成像阳性定义为至少1个前列腺影像报告和数据系统4或5分的可疑区域。
  • 采用逻辑回归构建2个模型:活检结局作为(1)单独前列腺癌预防试验风险计算器和(2)联合磁共振成像发现的函数。

主要发现

  • 全部患者中,联合磁共振成像模型与单独风险计算器模型表现相似(AUC=0.74 vs 0.78,P=.06)。
  • 预估高危(Gleason≥7)前列腺癌风险≤10%的患者中,联合磁共振成像模型优于单独模型(AUC=0.69 vs 0.60,P=.01)。
  • 该队列中,既往活检阴性者两模型区分度无显著差异(AUC=0.61 vs 0.63,P=.76)。
  • 该队列中,首次活检者联合磁共振成像模型区分度显著改善(AUC=0.72 vs 0.60,P=.01)。

关键数值与推荐

  • 磁共振成像阳性标准:至少1个前列腺影像报告和数据系统4或5分可疑区域。
  • 高危前列腺癌定义为Gleason≥7。
  • 风险分层阈值:预估高危前列腺癌风险≤10%。

临床怎么用

  • 作者认为,对于预估高危(Gleason≥7)前列腺癌风险≤10%的患者,应强烈考虑活检前行前列腺磁共振成像。
  • 本研究为回顾性分析,原文未据此给出其他临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the added value of prostate magnetic resonance imaging (MRI) to the Prostate Cancer Prevention Trial risk calculator. METHODS: Between January 2012 and December 2015, 339 patients underwent prostate MRI prior to biopsy at our institution. MRI was considered positive if there was at least 1 Prostate Imaging Reporting and Data System 4 or 5 MRI suspicious region. Logistic regression was used to develop 2 models: biopsy outcome as a function of the (1) Prostate Cancer Prevention Trial risk calculator alone and (2) combined with MRI findings. RESULTS: When including all patients, the Prostate Cancer Prevention Trial with and without MRI models performed similarly (area under the curve [AUC] = 0.74 and 0.78, P = .06). When restricting the cohort to patients with estimated risk of high-grade (Gleason ≥7) prostate cancer ≤10%, the model with MRI outperformed the Prostate Cancer Prevention Trial alone model (AUC = 0.69 and 0.60, P = .01). Within this cohort of patients, there was no significant difference in discrimination between models for those with previous negative biopsy (AUC = 0.61 vs 0.63, P = .76), whereas there was a significant improvement in discrimination with the MRI model for biopsy-naïve patients (AUC = 0.72 vs 0.60, P = .01). CONCLUSION: The use of prostate MRI in addition to the Prostate Cancer Prevention Trial risk calculator provides a significant improvement in clinical risk discrimination for patients with estimated risk of high-grade (Gleason ≥7) prostate cancer ≤10%. Prebiopsy prostate MRI should be strongly considered for these patients.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Kim EH, Weaver JK, Shetty AS, et al. Magnetic Resonance Imaging Provides Added Value to the Prostate Cancer Prevention Trial Risk Calculator for Patients With Estimated Risk of High-grade Prostate Cancer Less Than or Equal to 10. Urology. 2016. PMID: 27919668. doi:10.1016/j.urology.2016.08.074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。